Literature DB >> 15153324

Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?

S J Otto1, F H Schröder, H J de Koning.   

Abstract

OBJECTIVES: The likelihood of self-selection bias in a cohort of men that entered the volunteer-based randomised prostate cancer screening trial was assessed. In addition, the accuracy of the randomisation was evaluated by comparison amongst the trial arms.
SETTING: The Rotterdam section of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Participants were recruited from population registries and randomised after receipt of written informed consent (49% participation rate).
METHODS: Data from 37,614 men who entered the Rotterdam trial between June 1994 and July 1999 were linked to the Causes of Death Registry of Statistics Netherlands. For the assessment of self-selection bias, mortality in the trial cohort and the area of Rotterdam was compared by calculating standardised mortality ratios (SMRs, 95% confidence interval [CI]). Comparisons between the screening and the control arm were made by means of relative risk (RR).
RESULTS: There were a total of 1661 deaths (4.4%) in the trial cohort, during an average follow-up time of 2.8 years. The observed number of deaths in the two arms combined was lower than expected (SMR 86.7%, 95% CI 81.6-92.1), which was reflected in the major cause of death categories, especially in all malignant neoplasms. No difference was observed in the all-cause mortality rate among the screening and control arm, aged 55-69 years at entry (RR 1.00, 95% CI 0.89-1.12), nor when all causes, excluding prostate cancer mortality, were considered.
CONCLUSIONS: The preliminary results show that the screening and the control arm were comparable, but men recruited for the trial seemed healthier than men in the target population.

Entities:  

Mesh:

Year:  2004        PMID: 15153324     DOI: 10.1258/096914104774061074

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  10 in total

1.  Aerobic training restores arterial baroreflex sensitivity in older adults with type 2 diabetes, hypertension, and hypercholesterolemia.

Authors:  Kenneth M Madden; Chris Lockhart; Tiffany F Potter; Darcye Cuff
Journal:  Clin J Sport Med       Date:  2010-07       Impact factor: 3.638

2.  A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality.

Authors:  Marco Zappa; Donella Puliti; Jonas Hugosson; Fritz H Schröder; Pim J van Leeuwen; Ries Kranse; Anssi Auvinen; Sigrid Carlsson; Maciej Kwiatkowski; Vera Nelen; Alvaro Paez Borda; Monique J Roobol; Arnauld Villers
Journal:  Eur Urol       Date:  2014-01-07       Impact factor: 20.096

3.  Complications of initial prostate biopsy in a European randomized screening trial.

Authors:  Suzanne van den Heuvel; Stacy Loeb; Xiaoye Zhu; Paul Cms Verhagen; Fritz H Schröder; Chris H Bangma; Monique J Roobol
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

4.  Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.

Authors:  Xiaoye Zhu; Pim J van Leeuwen; Erik Holmberg; Meelan Bul; Sigrid Carlsson; Fritz H Schröder; Monique J Roobol; Jonas Hugosson
Journal:  J Med Screen       Date:  2012-09       Impact factor: 2.136

5.  Survival advantage of cohort participation attenuates over time: results from three long-standing community-based studies.

Authors:  Zihe Zheng; Casey M Rebholz; Kunihiro Matsushita; Judith Hoffman-Bolton; Michael J Blaha; Elizabeth Selvin; Lisa Wruck; A Richey Sharrett; Josef Coresh
Journal:  Ann Epidemiol       Date:  2020-04-03       Impact factor: 3.797

6.  Volunteer effect and compromised randomization in the Mayo Project of screening for lung cancer.

Authors:  Lorenzo Dominioni; Albino Poli; William Mantovani; Nicola Rotolo; Andrea Imperatori
Journal:  Eur J Epidemiol       Date:  2010-10-23       Impact factor: 8.082

7.  Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.

Authors:  Eleanor I Walsh; Emma L Turner; J Athene Lane; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin
Journal:  Trials       Date:  2016-10-13       Impact factor: 2.279

8.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population.

Authors:  Anna Fry; Thomas J Littlejohns; Cathie Sudlow; Nicola Doherty; Ligia Adamska; Tim Sprosen; Rory Collins; Naomi E Allen
Journal:  Am J Epidemiol       Date:  2017-11-01       Impact factor: 4.897

9.  Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer.

Authors:  Lionne D F Venderbos; Shafak Aluwini; Monique J Roobol; Leonard P Bokhorst; Eric H G M Oomens; Chris H Bangma; Ida J Korfage
Journal:  Qual Life Res       Date:  2017-02-06       Impact factor: 4.147

10.  Participation in a Prospective Cohort Study on Melanoma did not Affect the Incidence and Mortality of the Studied Disease.

Authors:  Åsa M Ingvar; Håkan Olsson; Per Broberg; Karolin Isaksson; Christian Ingvar; Kari Nielsen
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.